Answers are grounded in this paper and cite their sources.
Background No randomized studies have compared low‐dose or high‐dose concurrent chemoradiotherapy (CRT). Methods In this study, 7219 patients with stage III or IV head and neck squamous cell carcinoma (HNSCC) were enrolled and categorized into 2 groups: group 1, comprising those undergoing low‐dose concurrent CRT (n = 1575), and group 2, comprising those receiving high‐dose concurrent CRT (n = 5644). Results Cox regression analyses revealed that age ≥65 years, male, high Charlson comorbidity index (CCI) scores, radiotherapy (RT) duration ≥7.5 weeks, clinical stage IV cancer, oral cavity cancers, tobacco smoking, and total cisplatin dose ≥240 mg/m2 were significant independent prognostic risk factors for overall survival (OS). After adjustment for confounders, the adjusted hazard ratio (aHR; 95% confidence interval [CI]) for overall mortality was 0.83 (0.78‐0.89; P < .001) in patients with oral cavity HNSCC undergoing high‐dose concurrent CRT and 0.82 (0.77‐0.94; P < .001) in patients with nonoral cavity HNSCC receiving high‐dose concurrent CRT. Conclusion High‐dose concurrent CRT can reduce the incidence of death in patients with stage III or IV HNSCC.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: